I thought I had cancer, I never in a million years thought she was going to show me a baby," Krista Sciscoe, 33, told ...

Alcohol use disorder may predispose patients to worse adverse in-hospital outcomes after radical cystectomy and ileal conduit urinary diversion for bladder cancer.

Shares of ImmunityBio IBRX surged 17.4% after it announced a recent face-to-face meeting with senior FDA officials to align ...

Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...

Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer$25 million advanced at close of the ...

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

ANKTIVA is an Interleukin-15 (IL-15) receptor agonist that helps develop and activate key cells that work to destroy cancer cells. ・The company presented an overview of the clinical status of its ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.

Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...

Only 18% of NMIBC patients say they have frequent discussions with their HCPs about all available procedures/treatment options for NMIBC during most or every visit, yet most patients (92%) say they ...